SILENCE THERAPEUTICS PLC-ADR (SLN) Stock Analyst Ratings
USA - NASDAQ:SLN - US82686Q1013 - ADR
6.61 USD
-0.55 (-7.68%)
6.5 USD
-0.11 (-1.66%)
ChartMill assigns a Buy % Consensus number of 85% to SLN. The Buy consensus is the weighted average rating of the current analysts ratings.
SLN was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about SLN.
In the previous month the buy percentage consensus was at a similar level.
SLN was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-05-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-03-04 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-02-11 | Goldman Sachs | Initiate | Sell |
| 2025-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-08 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2024-08-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-06-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-06-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
SILENCE THERAPEUTICS PLC-ADR / SLN FAQ
Can you provide the consensus rating for SILENCE THERAPEUTICS PLC-ADR stock?
The consensus rating for SILENCE THERAPEUTICS PLC-ADR (SLN) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed SILENCE THERAPEUTICS PLC-ADR (SLN)?
The number of analysts covering SILENCE THERAPEUTICS PLC-ADR (SLN) is 5.